Gensenta İlaç stands as a prominent player in the pharmaceutical industry, leveraging a history dating back to 1923. Originally known as Mustafa Nevzat İlaç, the company was acquired by Amgen in 2012 and rebranded as Gensenta in 2020. Under the umbrella of Eczacıbaşı Topluluğu since November 2022, Gensenta aims to broaden its geographical reach and offer new, comprehensive solutions to healthcare challenges.
Gensenta is a major pharmaceutical and active pharmaceutical ingredient (API) manufacturer in Turkey, renowned for its singular penicillin production facility. The company's FDA-approval in 2006 positioned it as a pioneer among Turkish drug manufacturers. Gensenta's adherence to global standards such as cGMP and cGLP, along with its ISO 14001 – 45001 – 50001 certified operations, ensure its high-quality output.
With a team of 600 experts, Gensenta employs modern technology to manufacture products that serve health markets both domestically and internationally. It continues to seek strategic opportunities to enhance access and innovate in the healthcare landscape.